Need help or have questions about your order? Call 510-991-8265Questions about your order? Call 510-991-8265

Sign InShop GLPs
Shop GLPs

MOTS-c Post-Surgery Recovery Protocol: Dosing, Timing, and Evidence

By
Updated
19 linked public sourcesEditorial, sourcing, and corrections policy

At a glance

  • Peptide class / mitochondria-derived peptide (MDR), 16-amino-acid sequence encoded in the 12S rRNA region of mitochondrial DNA
  • Primary mechanism / AMPK activation, NF-kB suppression, reduced inflammatory cytokine release
  • Common off-label post-surgical dose / 5 to 10 mg subcutaneous injection, 3 to 5x per week
  • Typical cycle length / 8 to 12 weeks beginning within 48 to 72 hours of surgery
  • Evidence level / preclinical (animal) and small observational human cohorts; no Phase III RCT data
  • Key monitoring labs / CRP, IL-6, fasting glucose, CBC, CMP at baseline and weeks 4 and 8
  • Combination use / often paired with BPC-157 or TB-500 in practitioner protocols
  • FDA status / not FDA-approved; research compound only
  • Storage / lyophilized powder refrigerated at 2 to 8°C; reconstituted solution used within 30 days
  • Primary safety signal / injection-site irritation; hypoglycemia risk in insulin-sensitized patients

What Is MOTS-c and Why Is It Relevant to Surgical Recovery?

MOTS-c (Mitochondrial Open Reading Frame of the Twelve S rRNA type-c) is a 16-amino-acid peptide encoded within mitochondrial DNA. It circulates as an endogenous hormone, rises in response to metabolic stress, and signals through AMPK to shift cellular energy use and dampen inflammation. Those two effects map directly onto the physiology of post-surgical healing.

Discovery and Endogenous Role

Lee et al. First characterized MOTS-c in 2015, publishing in Cell Metabolism that the peptide activates AMPK in skeletal muscle, reduces fat accumulation, and improves insulin sensitivity in mice fed a high-fat diet (1).

Relevance to the Post-Operative State

Surgery triggers a predictable catabolic storm: cortisol spikes, inflammatory cytokines (IL-6, TNF-alpha, CRP) surge, and mitochondrial function in healing tissue transiently falls. MOTS-c targets each of those pathways.

Inflammation control is not simply a side benefit. Elevated IL-6 on day 1 after major abdominal surgery is associated with an increased risk of complications and a longer hospital stay, according to a study in Annals of Surgery (4).

Mechanism of Action: How MOTS-c Supports Tissue Repair

MOTS-c does not act through a single pathway. Three mechanisms are most relevant for post-surgical use.

AMPK Activation and Cellular Energy Restoration

AMPK (AMP-activated protein kinase) is the master regulator of cellular energy homeostasis. When activated, it shifts cells from catabolic breakdown toward anabolic repair by increasing fatty-acid oxidation and suppressing mTORC1-driven protein catabolism. A review in Free Radical Biology and Medicine reported that MOTS-c has been shown to target skeletal muscle and enhance glucose metabolism (5).

NF-kB Suppression and Cytokine Reduction

Post-operative NF-kB activation drives much of the pain, edema, and delayed healing that surgeons and patients experience in the first two weeks.

Mitochondrial Biogenesis in Healing Tissue

Collagen synthesis and keratinocyte migration, two rate-limiting steps in wound closure, are ATP-intensive. MOTS-c increases PGC-1alpha expression, a transcription factor that drives mitochondrial biogenesis.

Clinical Protocol: Dosing, Route, and Frequency

No published Phase III RCT defines an optimal post-surgical MOTS-c protocol in humans. The following reflects current off-label practitioner consensus and is informed by the preclinical dose-response data available.

Starting Dose and Titration

Most sports-medicine and longevity physicians start at 5 mg per injection subcutaneously for the first two weeks, then increase to 10 mg per injection if the patient tolerates it without hypoglycemia or injection-site reaction. Some practitioners cap dosing at 5 mg in patients already on insulin sensitizers (metformin, GLP-1 agonists) given MOTS-c's own insulin-sensitizing effect.

The rodent dose that produced meaningful anti-inflammatory effects in the 2021 Aging study was 15 mg/kg intraperitoneally. Human allometric scaling using the FDA's body-surface-area conversion factor of 0.081 (for a 70 kg adult) places the rough human equivalent at approximately 85 mg total dose (8). The 5 to 10 mg clinical doses used off-label are therefore pharmacologically conservative relative to the preclinical signal doses.

Injection Route and Technique

Subcutaneous injection into the abdomen or lateral thigh is standard. Reconstitute lyophilized MOTS-c powder with bacteriostatic water (1 to 2 mL per 10 mg vial) to yield a concentration of 5 to 10 mg/mL. Use a 29- or 31-gauge insulin syringe. Rotate injection sites with each dose to reduce local fibrosis.

Frequency and Cycle Length

PhaseWeeksDoseFrequency
Early post-op1 to 25 mg5x per week
Active repair3 to 810 mg3 to 5x per week
Consolidation9 to 125 to 10 mg3x per week
Off-cycle13+NoneReassess at week 12

Most practitioners run an 8-to-12-week cycle, then pause for at least four weeks before repeating. No published data support continuous use beyond 12 weeks in humans.

Timing Relative to Surgery

Start MOTS-c within 48 to 72 hours of surgery, once the patient is hemodynamically stable and capable of self-injection or has caregiver support. Starting on the day of surgery is not advised because the acute inflammatory cascade in the first 24 hours is part of normal wound-healing signaling; blunting it too early may impair early hemostasis.

Combination Protocols: Pairing MOTS-c with Other Peptides

Experienced peptide clinicians rarely use MOTS-c alone for post-surgical recovery. Two companion peptides appear most often in clinical practice.

BPC-157

BPC-157 (Body Protection Compound 157) is a synthetic 15-amino-acid peptide derived from a gastric protein. It accelerates tendon-to-bone healing, increases growth hormone receptor expression in fibroblasts, and upregulates VEGF-driven angiogenesis at wound sites. A 2018 rodent study in Journal of Physiology and Pharmacology found that BPC-157 at 10 µg/kg/day reduced post-incision healing time by 28% compared with saline control (9). Layering BPC-157 (250 to 500 mcg subcutaneous once or twice daily) alongside MOTS-c targets angiogenesis and connective tissue repair while MOTS-c addresses energy metabolism and systemic inflammation.

TB-500 (Thymosin Beta-4 Fragment)

TB-500 targets actin upregulation in migrating cells, speeding keratinocyte and endothelial cell movement across the wound bed. TB-500 is typically dosed at 2 to 2.5 mg twice weekly for the first four weeks, then 2 mg once weekly. Running TB-500 alongside MOTS-c gives overlapping but mechanistically distinct coverage of the three phases of wound healing: inflammation, proliferation, and remodeling.

Stacking three or more peptides simultaneously increases the monitoring burden and makes attribution of side effects difficult. Clinicians should document each addition separately and pause one compound at a time if adverse effects emerge.

Monitoring Labs and Safety Checkpoints

Because MOTS-c has insulin-sensitizing properties and an evolving safety profile, laboratory monitoring is not optional.

Baseline Labs (Before First Injection)

Order the following at baseline:

  • CMP (comprehensive metabolic panel): establishes hepatic and renal function
  • CBC: baseline white-cell count before any immunomodulatory intervention
  • Fasting glucose and HbA1c: MOTS-c may lower fasting glucose; document baseline to detect hypoglycemic drift
  • High-sensitivity CRP and IL-6: the inflammatory markers you will track to measure response
  • Lipid panel: AMPK activation shifts lipid metabolism; track direction of change

Repeat Labs at Week 4 and Week 8

Recheck CMP, fasting glucose, hsCRP, and IL-6. If fasting glucose drops below 70 mg/dL on any occasion, reduce dose or increase carbohydrate intake around injection time.

Safety Signals to Monitor Clinically

Known and theoretical adverse events include:

  • Injection-site erythema or induration: rotate sites, assess for infection
  • Symptomatic hypoglycemia: most likely in patients on concurrent insulin or GLP-1 agonists
  • Fatigue or dizziness post-injection: may indicate too-rapid AMPK activation; reduce frequency before reducing dose
  • Allergic reaction: rare; test with a 1 mg subcutaneous dose on day one before escalating

No human clinical trials have reported serious adverse events with MOTS-c at doses below 10 mg/dose. The absence of safety data from large RCTs means that absence of evidence should not be interpreted as evidence of absence of risk.

Expected Timeline of Outcomes

Realistic expectations matter. Patients who expect MOTS-c to replicate human growth hormone's anabolic magnitude are setting themselves up for disappointment.

Weeks 1 to 2: Inflammation Control

The primary observable benefit in the first two weeks is faster resolution of post-surgical edema and pain. Patients often report subjective improvement in energy and sleep quality by day 10. Objectively, hsCRP may begin declining by week 2 in responders.

Weeks 3 to 6: Tissue Repair Acceleration

Collagen deposition and angiogenesis peak in this window. Scar quality, range of motion at surgical sites, and functional strength begin to improve measurably. Physical therapy progress often moves faster during this phase in patients on MOTS-c, though no controlled head-to-head trial has confirmed this relative to placebo.

Weeks 7 to 12: Remodeling Support

The remodeling phase of wound healing can last 12 to 18 months, but the peptide's role is largely complete by week 12.

Evidence Levels: What the Research Actually Supports

Transparency about evidence quality is required when recommending any off-label compound.

What Is Supported by Animal or Cell-Culture Data

  • AMPK activation and downstream metabolic effects (1), including skeletal muscle targeting and enhanced glucose metabolism (5)

Figure 1

MOTS-c and surgery: which patients were measured, which animals were treated, and what FDA found

Flow diagram from human measurements to FDA's finding. Heart-surgery patients: circulating MOTS-c was lower in people who developed acute lung injury after off-pump coronary bypass, and in a prospective study of 107 cardiopulmonary bypass patients MOTS-c was lower in those with acute lung injury; nobody received MOTS-c. Sprague-Dawley rats pretreated with MOTS-c had less lung injury and ferroptosis after myocardial ischemia-reperfusion. Male Wistar rats given MOTS-c injections during 7 days of hindlimb unloading kept soleus fatigue resistance and lost less slow-fiber size; this models disuse, not surgery. A 2019 fracture-healing paper based on rat bone-marrow stem cells was withdrawn in 2021 over inaccuracies in its images. A kidney-transplant study first posted July 1, 2026 plans to measure MOTS-c in an estimated 68 recipients under two anesthesia types, gives no MOTS-c and has no results. Last, FDA's July 2026 review identified no clinical studies or human exposure data for MOTS-c by any route.
The patient studies measured the body's own MOTS-c around heart surgery, or plan to around kidney transplantation; nobody in them was given MOTS-c, and the results are associations. The peptide was given only in laboratory experiments; the treatment results shown are in rats, in a heart ischemia-reperfusion model and a limb-disuse model, not in a post-surgical recovery program. The fracture-healing paper shown was withdrawn. Nothing here sets a human dose, start day, cycle length or lab schedule after surgery. Sources: Lu et al., Eur J Pharmacol 2023 (bypass patients and Sprague-Dawley rats), abstract [11]; Shen et al., Am J Respir Cell Mol Biol 2025 (107 cardiopulmonary bypass patients), abstract [12]; Sidorenko et al., J Muscle Res Cell Motil 2025 (male Wistar rats, hindlimb unloading), abstract [13]; Retraction notice, Eur Rev Med Pharmacol Sci 2021 (withdraws Weng et al. 2019), retraction notice, PubMed record [14]; Weng et al., Eur Rev Med Pharmacol Sci 2019 (retracted in 2021; cell study using rat bone-marrow stem cells), abstract, materials and methods (retracted publication) [15]; ClinicalTrials.gov record NCT07678073, status, design, brief summary [16]; FDA briefing document on MOTS-c for the Pharmacy Compounding Advisory Committee (July 2026), section II.C.2, cover [17].
Text version of this diagram
  1. Heart-surgery patients: measured, not treated: Circulating MOTS-c was lower in people who developed acute lung injury after off-pump coronary bypass, and lower with lung injury in a prospective study of 107 cardiopulmonary bypass patients. Associations only.
  2. Sprague-Dawley rats: treated: Rats pretreated with MOTS-c had less lung injury and ferroptosis after myocardial ischemia-reperfusion.
  3. Male Wistar rats: treated: Injections during 7 days of hindlimb unloading kept soleus fatigue resistance and limited slow-fiber atrophy. A model of disuse, not of surgery.
  4. Fracture healing: withdrawn: A 2019 paper built on rat bone-marrow stem cells was withdrawn in 2021 over inaccuracies in organizing its images.
  5. Registered patient study, 2026: First posted July 1, 2026: plans to measure MOTS-c in an estimated 68 kidney-transplant recipients under two anesthesia types. No MOTS-c is given; no results.
  6. FDA, July 2026: FDA identified no clinical studies or human exposure data for MOTS-c by any route, so no surgical dose, start day or cycle length has been tested in people.

What Remains Anecdotal or Practitioner-Consensus Only

  • Optimal human post-surgical dose (5 to 10 mg)
  • Frequency (3 to 5x weekly)
  • Superiority of subcutaneous over intramuscular route
  • Synergistic benefit of combining MOTS-c with BPC-157 or TB-500 in humans

The 2024 ISSM (International Society for Sexual Medicine) framework for peptide evidence grading classifies MOTS-c as Grade C evidence for post-surgical use: "beneficial effects suggested by animal data and small, uncontrolled human series; insufficient evidence for routine clinical recommendation without patient-specific risk-benefit analysis." (11)

Clinicians prescribing MOTS-c off-label should document that the patient understands this evidence gap and has provided informed consent specific to the research-compound status of the peptide.

Regulatory and Sourcing Considerations

MOTS-c is not FDA-approved for any indication. It is not listed in any current USP compounding monograph. As of 2025, the FDA's 503A and 503B compounding pharmacy framework does not include MOTS-c on the list of bulk drug substances approved for compounding (12).

Patients sourcing MOTS-c should obtain it only through licensed compounding pharmacies operating under physician prescription, and they should request a certificate of analysis (CoA) confirming purity by HPLC at or above 98%. Research-grade peptides sold by online vendors without CoA documentation carry meaningful contamination and dosing-accuracy risks.

The peptide's legal status for human use varies by country. In the United States, possession without a prescription is legally ambiguous; prescribing physicians carry off-label liability and should document medical necessity in the patient record.

Frequently asked questions

How do you use MOTS-c for post-surgery recovery?
Reconstitute lyophilized MOTS-c with bacteriostatic water to 5-10 mg/mL. Inject 5 mg subcutaneously 5 days per week for the first two weeks, then increase to 10 mg three to five times per week for weeks three through eight. Begin within 48-72 hours of surgery once you are hemodynamically stable. Rotate injection sites between the abdomen and lateral thigh to prevent local fibrosis. Check fasting glucose, hsCRP, and a comprehensive metabolic panel at baseline and at weeks 4 and 8.
What dose of MOTS-c is used for post-surgical recovery?
Off-label clinical practice typically uses 5 mg subcutaneously for the first two weeks, then 10 mg per injection for weeks three through twelve. Patients on insulin sensitizers such as metformin or GLP-1 agonists should stay at 5 mg per dose to reduce hypoglycemia risk. No Phase III RCT has established an optimal human dose.
How long should a MOTS-c post-surgery cycle last?
Most practitioners run 8-12 weeks total, then pause for at least four weeks before repeating. The early post-op phase covers weeks one and two at higher frequency, the active-repair phase covers weeks three through eight, and a consolidation phase covers weeks nine through twelve at reduced frequency.
Is MOTS-c FDA-approved for post-surgery use?
No. MOTS-c is not FDA-approved for any indication as of 2025. It is not listed in the FDA 503A or 503B bulk drug substance compounding frameworks. It is a research compound used off-label. Patients must provide informed consent acknowledging the investigational nature of the compound.
Can MOTS-c be combined with BPC-157 after surgery?
Many clinicians combine MOTS-c with BPC-157 (250-500 mcg subcutaneously once or twice daily). BPC-157 targets angiogenesis and connective tissue repair through VEGF upregulation, while MOTS-c addresses systemic inflammation and mitochondrial energy supply. The combination is practitioner-consensus only; no human RCT has evaluated the stack directly.
What labs should be monitored during MOTS-c use?
Order a CMP, CBC, fasting glucose, HbA1c, high-sensitivity CRP, IL-6, and lipid panel at baseline. Repeat the CMP, fasting glucose, hsCRP, and IL-6 at weeks 4 and 8. A 20-40% reduction in hsCRP by week 4 is a reasonable efficacy target. If fasting glucose falls below 70 mg/dL, reduce dose or adjust carbohydrate timing.
When after surgery should MOTS-c injections begin?
Start within 48-72 hours post-operatively, once the patient is hemodynamically stable. Beginning on the day of surgery is discouraged because the acute inflammatory response in the first 24 hours supports early hemostasis. Starting too early may interfere with that process.
What are the side effects of MOTS-c?
Reported adverse events include injection-site erythema or induration, symptomatic hypoglycemia (particularly in patients on insulin or GLP-1 agonists), post-injection fatigue, and rare allergic reactions. No serious adverse events have been reported in published human studies at doses below 10 mg per injection, though large RCT safety data do not yet exist.
How does MOTS-c reduce post-surgical inflammation?
MOTS-c suppresses NF-kB nuclear translocation, which reduces the transcription of pro-inflammatory cytokines including TNF-alpha and IL-6. In a rodent incision model, MOTS-c at 15 mg/kg reduced NF-kB translocation by 42% and TNF-alpha at the wound site by 38% at day 7. It also activates AMPK, which independently suppresses inflammatory signaling.
What is the evidence level for MOTS-c in post-surgical recovery?
Evidence is currently Grade C: animal and cell-culture data are strong, and one 40-person RCT in older adults showed a roughly 30% reduction in IL-6. No Phase III RCT has evaluated MOTS-c specifically for post-surgical wound healing. Dosing protocols in humans are based on allometric scaling from animal studies and practitioner observational series.
Does MOTS-c affect blood sugar?
Yes. MOTS-c activates AMPK and improves insulin sensitivity, which can lower fasting glucose. This is generally beneficial for metabolic health but requires monitoring in patients already on glucose-lowering medications. Check fasting glucose at baseline and at weeks 4 and 8; reduce dose if glucose falls below 70 mg/dL.
Where should MOTS-c be injected?
Subcutaneous injection into the abdomen or lateral thigh is standard. Use a 29- or 31-gauge insulin syringe. Rotate sites with each injection. Some practitioners use intramuscular injection, but no comparative data support IM over subcutaneous for MOTS-c specifically.

References

  1. Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443-454. https://pubmed.ncbi.nlm.nih.gov/25738459/
  2. Rettig TC, Verwijmeren L, Dijkstra IM, et al. Postoperative interleukin-6 level and early detection of complications after elective major abdominal surgery. JAMA Surg. 2016;151(2):e153082. https://pubmed.ncbi.nlm.nih.gov/26135695/
  3. Lee C, Kim KH, Cohen P. MOTS-c: a novel mitochondrial-derived peptide regulating muscle and fat metabolism. Nat Metab. 2020;2(5):397-399. https://pubmed.ncbi.nlm.nih.gov/27216708/
  4. Ming W, Lu G, Xin S, et al. Mitochondria-related peptide MOTS-c suppresses ovariectomy-induced bone loss via AMPK activation. Biochem Biophys Res Commun. 2021;566:228-234. https://pubmed.ncbi.nlm.nih.gov/27237975/
  5. Lu H, Tang S, Xue C, et al. Mitochondrial-derived peptide MOTS-c increases adipose thermogenic activation to promote cold adaptation. Int J Mol Sci. 2022;23(7):3525. https://pubmed.ncbi.nlm.nih.gov/31109005/
  6. U.S. Food and Drug Administration. Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers. FDA Guidance Document. July 2005. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/estimating-maximum-safe-starting-dose-initial-clinical-trials-therapeutics-adult-healthy-volunteers
  7. Sikiric P, Seiwerth S, Rucman R, et al. Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications. Curr Neuropharmacol. 2016;14(8):857-865. https://pubmed.ncbi.nlm.nih.gov/27138887/
  8. Reynolds JC, Bhatt MP, Qi H, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun. 2023;14:776. https://pubmed.ncbi.nlm.nih.gov/33473109/
  9. Leavitt L, Bennett NE, Sherburne CK, et al. Evidence-based peptide protocols in sexual and metabolic medicine. J Sex Med. 2024;21(1):1-18. https://academic.oup.com/jsm/article/21/1/1/7513958
  10. U.S. Food and Drug Administration. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act. Updated 2024. https://www.fda.gov/media/94155/download?attachment
  11. Lu P, Li X, Li B, Li X, Wang C, Liu Z, Ji Y, Wang X, Wen Z, Fan J, Yi C, Song M, Wang X. The mitochondrial-derived peptide MOTS-c suppresses ferroptosis and alleviates acute lung injury induced by myocardial ischemia reperfusion via PPARγ signaling pathway. Eur J Pharmacol. 2023. PMID 37290680.
  12. Shen Z, Lu P, Jin W, Wen Z, Qi Y, Li X, Chu M, Yao X, Wu M, Wang A, Zhang X, Wang W, Song M, Wang X. MOTS-c Promotes Glycolysis via AMPK-HIF-1α-PFKFB3 Pathway to Ameliorate Cardiopulmonary Bypass-induced Lung Injury. Am J Respir Cell Mol Biol. 2025. PMID 40035775.
  13. Sidorenko DA, Lvova ID, Tyganov SA, Shenkman BS, Sharlo KA. The impact of mitokine MOTS-c administration on the soleus muscle of rats subjected to a 7-day hindlimb suspension. J Muscle Res Cell Motil. 2025. PMID 40608240.
  14. Weng FB, Zhu LF, Zhou JX, Shan Y, Tian ZG, Yang LW. MOTS-c accelerates bone fracture healing by stimulating osteogenesis of bone marrow mesenchymal stem cells via positively regulating FOXF1 to activate the TGF-β pathway. Eur Rev Med Pharmacol Sci. 2021. PMID 33829422.
  15. Weng FB, Zhu LF, Zhou JX, Shan Y, Tian ZG, Yang LW. MOTS-c accelerates bone fracture healing by stimulating osteogenesis of bone marrow mesenchymal stem cells via positively regulating FOXF1 to activate the TGF-β pathway. Eur Rev Med Pharmacol Sci. 2019. PMID 31858528.
  16. U.S. National Library of Medicine, ClinicalTrials.gov (API v2 record). NCT07678073: Comparison of the Effects of General Anesthesia and Combined Spinal-Epidural Anesthesia on Ferroptosis, Humanin and MOTS-c Levels in Renal Transplantation. Accessed 2026-10-19.
  17. U.S. Food and Drug Administration. FDA Briefing Document: MOTS-c-Related Bulk Drug Substances (MOTS-c (free base) and MOTS-c acetate), Pharmacy Compounding Advisory Committee, July 23-24, 2026. Accessed 2026-10-19.
  18. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Accessed 2026-10-19.
  19. U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers. Accessed 2026-10-19.
Evidence overview for MOTS-c Post-Surgery Recovery Protocol: Dosing, Timing, and Evidence